The rising prevalence in GLP-1 agonists for diabetes has led to a debate about application forms : skin-applied devices versus tablets . Typically, GLP-1 therapies were exclusively available in oral https://agnesvzdm636781.liberty-blog.com/41249268/glp-1-transdermal-delivery-systems-vs-pills-is-right-for-the-patient